large-scale production of hepatocytes from a variety of genetic backgrounds would be beneficial for drug screening and to provide a source of cells to be used as a substitute for liver transplantation. However, fully functional primary hepatocytes remain difficult to expand in vitro, and circumventing this problem by using an alternative source of cells is desirable. Here we describe a 25-d protocol to direct the differentiation of human pluripotent stem cells into a near-homogenous population of hepatocyte-like cells. as cells progress through this protocol, they express genes in a chronological manner similar to that described during in vivo hepatic development. the protocol relies on culture systems devoid of serum, feeders or complex extracellular matrices, which enable molecular analyses without interference from unknown factors. this approach works efficiently with human embryonic stem cells and human induced pluripotent stem cells and was recently used to model liver diseases in vitro. The protocol comprises four stages, which mimic the embryonic development of the liver and enable the production of differentiated cells following a natural path of development. The procedure starts at the beginning of the differentiation protocol, with splitting and experimental plate setup. This day is designated day 0 (D0). In the first stage, hPSCs are differentiated into definitive endoderm (DE) cells, which represent the earliest precursors of all endodermal organs (liver, pancreas, lung, gut and thyroid). The second stage differentiates these DE cells into anterior definite endoderm (ADE) cells, which represent a common progenitor between the liver, pancreas, lung and thyroid. During the third stage, ADE cells differentiate into hepatic progenitors. During the fourth and final stage of the protocol, the resulting hepatocyte-like cells undergo functional maturation. Each stage is marked by the expression of specific genes, and the hepatocyte-like cells obtained after 25 d of differentiation have functional characteristics shared by both fetal and adult hepatocytes, including ALB and A1AT secretion, glycogen storage, cholesterol uptake and inducible detoxification activity of cytochrome P450 enzymes such as CYP3A7 and CYP1A1. As maturation is continued, fetal characteristics begin to diminish, whereas functions associated with adult functionality increase to reach a maximum level at day 35.
IntroDuctIon
The liver has a very broad spectrum of functions during adult life. It processes consumed substances, sustains reserves of iron, vitamins and minerals, stores glycogen and produces bile for digestion of lipids, albumin (ALB) and blood clotting factors. Finally, the liver detoxifies alcohol, drugs and other chemicals, and it removes inhaled poisons such as exhaust or smoke, all of which accumulate in the bloodstream. Most of these activities are managed by one cell type, the hepatocyte, which constitutes the main cellular unit of the liver.
End-stage liver disease that targets one or several of these critical liver functions must be dealt with by orthotopic liver transplantation, as only a healthy donor liver can restore the missing metabolic function. However, this ultimate solution does not represent a cure, as it has a high risk of surgical complications, indefinite immunosuppression associated with severe side effects and eventual organ rejection. Furthermore, although the number of organ donors has remained constant over the past 10 years, the demand for liver transplantation has more than doubled. This situation is likely to continue to worsen in the foreseeable future because of a Hepatitis C pandemic and increases in cirrhosis associated with obesity. Thus, the development of alternative therapies to orthotopic liver transplantation has become a major objective in the field of regenerative medicine.
A cell-based therapeutic approach involving transplantation of healthy hepatocytes into the livers of disease-affected patients may facilitate a complete correction of all aspects of the clinical syndrome associated with liver failure. Such an approach already carries precedence within clinical practice, as nearly 100 patients suffering from inherited metabolic diseases have, to date, received donor hepatocytes to treat a variety of inherited liver diseases, including alpha-1 antitrypsin deficiency (A1ATD), glycogen storage disorders, ornithine carbamoyltransferase deficiency (OCTD), Crigler-Najjar syndrome and factor VII deficiency 1 . Similarly, the development of a bioartificial liver fueled with primary hepatocytes could represent an advantageous alternative for bridge therapy in individuals with acute liver failure. Primary hepatocytes are also needed by the pharmaceutical industry for diverse in vitro applications, including drug development and toxicology screening.
Unfortunately, all these applications are limited or impaired by the scarce number and quality of available donor cells. Indeed, primary hepatocytes are fully differentiated cells that are impossible to expand in vitro. As a consequence, hepatocytes can only be obtained from organ donation, and often only livers of poor quality are available for cell purification. For all these reasons, an alternative source of cells for generating fully functional hepatocytes is urgently needed.
Human pluripotent stem cells (hPSCs) derived from embryos at the blastocyst stage (human embryonic stem cells or hESCs) 2 or from reprogrammed fibroblasts by overexpression of pluripotency factors (human induced pluripotent stem cells or hIPSCs) 3 could represent an advantageous system to produce hepatocyte-like cells from a wide diversity of genetic backgrounds. Indeed, these pluripotent cells share the unique characteristic to self-renew in vitro while maintaining the capacity to differentiate into a broad number of cell types. By combining these unique properties, hESCs or hIPSCs could enable the generation of a large quantity of cells for clinical applications, including hepatocytes 4 .
Experimental design
Here we describe the protocol we used to derive the cells described in refs. 5, 6 . This protocol directs the differentiation of hPSCs into a nearhomogenous population of fetal-like hepatocytes that can undergo functional maturation following prolonged culture (Fig. 1) . This protocol has been validated with five hESC lines (H9, Val9, FES22/29 (ref. 7 ) and hSF-6) and 20 hIPSC lines to model inherited metabolic diseases including A1ATD, glycogen storage disorder 1-α and hypercholesterolemia 5, 6 ( Table 1) . The procedure uses chemically defined medium (CDM) devoid of serum and complex extracellular matrices such as Matrigel. Thus, this culture system could easily be transferred to good manufacturing practice conditions, and it avoids the presence of unknown factors that could interfere with molecular analyses.
The protocol comprises four stages, which mimic the embryonic development of the liver and enable the production of differentiated cells following a natural path of development. The procedure starts at the beginning of the differentiation protocol, with splitting and experimental plate setup. This day is designated day 0 (D0). In the first stage, hPSCs are differentiated into definitive endoderm (DE) cells, which represent the earliest precursors of all endodermal organs (liver, pancreas, lung, gut and thyroid). The second stage differentiates these DE cells into anterior definite endoderm (ADE) cells, which represent a common progenitor between the liver, pancreas, lung and thyroid. During the third stage, ADE cells differentiate into hepatic progenitors. During the fourth and final stage of the protocol, the resulting hepatocyte-like cells undergo functional maturation. Each stage is marked by the expression of specific genes, and the hepatocyte-like cells obtained after 25 d of differentiation have functional characteristics shared by both fetal and adult hepatocytes, including ALB and A1AT secretion, glycogen storage, cholesterol uptake and inducible detoxification activity of cytochrome P450 enzymes such as CYP3A7 and CYP1A1. As maturation is continued, fetal characteristics begin to diminish, whereas functions associated with adult functionality increase to reach a maximum level at day 35.
The distinct gene expression profile at each stage of the protocol can be used to determine the developmental time point of hepatic cells generated in vitro. For example, α-fetoprotein (encoded by AFP) 8 and cytochrome P450, family 3, subfamily A, polypeptide 7 (encoded by CYP3A7) represent, respectively, the major serum protein and cytochrome enzyme expressed by the liver during fetal life 9 , whereas high levels of ALB and CYP3A4 activity are found in hepatocytes from the adult liver 9 . The cells resulting from the protocol described below still express marked levels of AFP and CYP3A7 while also expressing adult hepatocyte markers such as α-1-antitrypsin, apolipoprotein-F (encoded by APOF), CYP1A1, CYP3A4, CYP1A2 and CYP1B1. Furthermore, the cells generated using this protocol show functional activity, including uptake of indocyanine green and cholesterol, inducible cytochrome P450 activity, and secretion of ALB and α-1-antitrypsin 5, 6 . Therefore, hepatic cells produced using the protocol described here could be intermediates between adult and fetal hepatocytes. However, only a systematic comparison between primary and fetal hepatocytes obtained at different stages of development will enable the definition of the precise level of maturity of hepatocytes generated in vitro. For these reasons, these cells are best described as a hepatocyte-like cell model. Despite the uncertainty surrounding their precise developmental identity, the hepatocyte-like cells derived using this protocol can be useful for modeling in vitro a broad number of inherited metabolic disorders 5 , and they are able to colonize the liver of an animal model for 8 weeks while maintaining the expression of ALB and SERPINA1 (ref. 6 ). Identification of the appropriate maturation period should be determined using primary hepatocytes as a positive control for the desired hepatic functionality and output, similar to the controls detailed below. With regard to genetic modification, genes can be easily overexpressed or knocked down in hepatocyte-like cells (approximately days 20-35) using the gene therapy approach. As an example, we have shown that a lentivirus vector containing an APOF promoter driving the expression of the GFP reporter gene can be useful in purifying artificial hepatocytes. Flow cytometry analyses showed that 85% of cells expressed GFP 3 d after transduction 10 .
Although this method has worked with the majority of hESCs and hIPSCs grown in our laboratory, ~20% of hIPSC lines seem to be resistant to endoderm differentiation, and thus we have not been able to generate hepatic cells from these lines. The variability between lines remains difficult to explain and can be partially corrected by optimizing the concentration of each growth factor especially during the first stage of the protocol. Indeed, DE differentiation appears to be the most crucial part of our approach, and thus we recommend that this stage be optimized in order to ensure successful differentiation toward the hepatic pathway. Furthermore, day 25 of this protocol represents the earliest time point at which these cells can be used to model basic hepatic metabolic function. However, cells differentiated at day 35 systematically show the highest level of ALB secretion and cytochrome P450 activity and thus represent the optimal stage for functional analyses such as toxicology screening. Finally, we recommend using primary hepatocytes (available from Lonza, Biopredict and Invitrogen) as a positive control for the basic characterizations performed on hepatocyte-like cells, especially quantitative PCR (qPCR) analyses, ALB secretion and CYP3A4 activity (representative analyses and expected outcomes are described in detail later). 
Tissue culture plates, six-well Gelatin/MEF-coated tissue culture plates Tissue culture tubes, 15 ml Tissue culture tubes, 50 ml Serological pipettes REAGENT SETUP Serum-containing medium for coating tissue culture plates (500 ml) Combine 450 ml of Advanced DMEM/F12, 50 ml of FBS, 5 ml of glutamine, 5 ml of pen/strep and 3.5 µl of β-mercaptoethanol. This medium can be stored at 4 °C for up to 1 month.  crItIcal Sterilize serum-containing medium using a 0.22-µm filtration device. Serum coating can be replaced by 15 g ml − 1 human fibronectin (Millipore, cat. no. 341635). However, this alternative is less cost-effective and might be less efficient with specific hIPSC lines. Thus, we recommend serum coating for routine use and for medium optimization with new hPSC lines. CDM-BSA medium for maintenance of hESCs (500 ml) Mix 2.5 g of BSA, 250 ml of Advanced DMEM/F12, 250 ml of IMDM, 5 ml of concentrated lipids, 20 µl of thioglycerol, 350 µl of insulin, 250 µl of transferrin and 5 ml of pen/strep. This medium can be stored at 4 °C for up to 1 month.  crItIcal Sterilize CDM-BSA medium using a 0.22-µm filtration device. The medium should be warmed to 37 °C before use. Each BSA batch must be screened for its ability to support undifferentiated growth on hESCs. Not all batches of BSA fraction V are suitable, and they must therefore be prescreened. We found suitable batches from Sigma-Aldrich, PAA and Europa Bioproducts. The quality of the resulting CDM-BSA should be compared against standard feeder cultures, with particular emphasis on the maintenance of colony morphology and undifferentiated growth characteristics, as well as continued expression of POU5F1, NANOG and SOX2 with early differentiation markers such as CDX2, T, MIXL1 and SOX17 at levels comparable to the feeder cultures. CDM-PVA medium for maintenance of hIPSCs and differentiation to endoderm (500 ml) Mix 0.5 g of PVA, 250 ml of F12 + GlutaMAX, 250 ml of IMDM, 5 ml of concentrated lipids, 20 µl of thioglycerol, 350 µl of insulin, 250 µl of transferrin and 5 ml of pen/strep. This medium can be stored at 4 °C for up to 1 month after opening.  crItIcal PVA needs to be dissolved in 50 ml of IMDM by placing 0.5 g of PVA in a 50-ml tube with IMDM and placed on a tube roller overnight at 4 °C. Sterilize CDM-PVA medium using a 0.22-µm filtration device. The medium should to be warmed to 37 °C before use. RPMI/B-27 differentiation medium for the differentiation of ADE and hepatoblast specification (500 ml) Mix 490 ml of RPMI-1640, 10 ml of B-27, 5 ml of NEAA and 5 ml of pen/strep. This medium should to be warmed to 37 °C before use. It can be stored at 4 °C for up to 3 weeks. Gelatin solution for coating tissue culture plates (500 ml) Combine 0.5 g of gelatin and 500 ml of embryo transfer water; heat the mixture to 56 °C until gelatin dissolves, and then cool it to room temperature (18-25 °C).  crItIcal Sterilize gelatin solution using a 0.22-µm filtration device. Gelatin may be stored for 4-8 weeks.
Collagenase for dissociation of hESCs and hIPSCs colonies (500 ml; use within 4 weeks) Mix 400 ml of Advanced DMEM/F12, 100 ml of KnockOut serum replacement medium, 5 ml of glutamine, 3.5 µl of β-mercaptoethanol and 500 mg of collagenase type IV; mix the contents by inversion.  crItIcal Sterilize collagenase using a 0.22-µm filtration device and then aliquot it into 50-ml tubes. Collagenase should to be warmed to 37 °C before use. Aliquots can be stored for 1 month at 4 °C. Hepatocyte basal medium (500 ml) Prepare hepatocyte basal medium according to the manufacturer's specifications, which are included in the BulletKit. Medium should to be warmed to 37 °C before use. This medium can be stored at 4 °C for up to 1 month. Dispase for dissociation of hIPSCs (500 ml) Mix and filter 500 mg of dispase with 500 ml of Advanced DMEM/F12. This medium can be stored at 4 °C for up to 1 month.  crItIcal Sterilize dispase using a 0.22-µm filtration device, and then aliquot it into 50-ml tubes. Dispase should to be warmed to 37 °C before use. Dispase/collagense (1:1) for passaging hIPSCs or hESCs Mix dispase and collagenase at a ratio of 1:1 to obtain the required volume for passaging cells. Dispase/collagenase (1:1) should to be warmed to 37 °C before use and should be used within 2 weeks.
•
Small molecules Dissolve LY294002 and CHIR99021 in DMSO at a stock concentration of 10 mM.  crItIcal Check that small molecules are well dissolved, and then store the stock at − 20 °C. Maintenance of hPSCs Maintain hPSCs in CDM containing activin A (10 ng ml − 1 ) and bFGF (12 ng ml − 1 ), as described in refs. 5,6,10 in a humidified tissue culture incubator at 37 °C, 5% CO 2 and atmospheric O 2 (ref. 11). The medium should be replaced daily, and all growth factors should be added directly to the medium before use.  crItIcal Differentiation efficacy can be increased by splitting hPSCs grown on feeders or in CDM directly to culture conditions inductive for mesoderm differentiation described below (CDM-PVA + activin + FGF2 + BMP4 + LY294002 + CHIR99021). See Figure 1 for a differentiation schematic. Fluorescenceactivated cell sorting (FACS) analyses can be performed to confirm that 80-90% of the cells express the pluripotency markers Oct4 and Tra-1-60. Growth factors cannot be kept at 4 °C for longer than 1 week, and basal medium cannot be kept for more than 4 weeks at 4 °C. All growth factors should be added directly to fresh medium each day; making bulk batches of medium containing growth factors is not advisable unless all of the medium will be used within 2-3 d. EQUIPMENT SETUP Gelatin/serum-coated tissue culture plates Coat the desired numbers of plates for maintenance and differentiation using gelatin solution at room temperature (18-25 °C) for 30 min. Aspirate the gelatin and replace it with serum-containing medium; place the plates at 37 °C for at least 24 h.  crItIcal Serum-coated plates must be prepared at least 24 h before use and can be stored at 37 °C for 7-14 d.
proceDure passaging hpscs for differentiation • tIMInG ~1 d 1| Day 0. Take hPSCs that are 80% confluent, aspirate the medium, and then wash the cells with 1 volume of Ca 2 + /Mg 2 + -free PBS (PBS − / − ). Minimal volumes will depend on the plate used; however, we recommend adding 0.5 ml per well of a 12-well plate, 1 ml per well of a six-well plate and 5 ml per 10-cm dish.
2|
Aspirate the PBS and replace it with a minimal volume of collagenase/dispase solution. Incubate the cells at 37 °C until 90% of the colonies entirely lift from the bottom of the plate (>30 min). Typically, most colonies will have detached from the bottom of the plate after 60 min.
3|
Transfer the cells to a 15-ml tube. Wash the colonies by centrifuging at 180g for 2 min at room temperature, removing the supernatant and resuspending them in CDM-PVA without cytokines. Repeat this wash, but resuspend the pellet in CDM-PVA containing activin and bFGF. The volume of CDM containing activin and bFGF should be appropriate to facilitate the appropriate splitting ratio.  crItIcal step hPSCs should be split so that after 6-8 d of culture the cells will be 80% confluent and ready for passaging again. This is usually obtained if cells are split at a ratio of 1:6-10. For example, one 10-cm tissue culture plate could be split into six to ten 10-cm tissue culture plates, six to ten six-well plates or six to ten 12-well plates as needed. However, this ratio will vary depending on the hESC or hIPSC line and must be determined by the user. For the cells we have used, a typical cell plating density is 200,000 cells per 10-cm plate.
4|
Resuspend the colonies using a 10-ml serological pipette to facilitate the breakup of large colonies into smaller pieces. For 12-well plates, take 1 ml of cell suspension and add it to 17 ml of CDM-PVA containing activin A and bFGF, and then distribute 1.5 ml of this cell suspension to each well of the 12-well plate. Induce differentiation by replacing the medium with freshly prepared CDM-PVA containing activin A (100 ng ml − 1 ), bFGF (100 ng ml − 1 ), BMP-4 (10 ng ml − 1 ), LY294002 (10 µM) and CHIR99021 (3 µM); incubate for 24 h only. The typical morphology of cells undergoing differentiation can be seen in Figure 2a .  crItIcal step CHIR99021 is included in the first day of differentiation only. It should not be included in any subsequent days of differentiation at any stage of the protocol. ? troublesHootInG 8| Day 3. Replace the medium with freshly prepared CDM-PVA containing activin A (100 ng ml − 1 ), bFGF (100 ng ml − 1 ), BMP-4 (10 ng ml − 1 ) and LY294002 (10 µM) . This change in medium should induce endoderm specification over the next 24 h. Incubate the cells for 24 h only. Typical morphology of cells undergoing differentiation can be seen in Figure 2b .  crItIcal step CHIR99021 should not be included in this or any subsequent day's medium changes. ? troublesHootInG 9| Day 4. Replace the medium with freshly prepared RPMI/B-27 medium containing activin A (100 ng ml − 1 ) and bFGF (100 ng ml − 1 ). This change in medium should lead to endoderm commitment over the next 24 h. Incubate the cells for 24 h. The typical morphology of cells undergoing differentiation can be seen in Figure 2c .  crItIcal step FACS analyses can be performed at the end of the 24-h incubation (on day 5) to confirm that 60-90% of the cells express the endoderm marker CXCR4 and/or SOX17. qPCR may also be performed to demonstrate SOX17 and CXCR4 expression and the absence of mesodermal cells (MIXL1, T gene expression), as well as extraembryonic cells (CDX2) and neuroectodermal cells (PAX6). ? troublesHootInG Differentiation to aDe • tIMInG ~3 d 10| . Aspirate the medium and replace it with RPMI/B-27 differentiation medium containing activin A (50 ng ml − 1 ). Incubate the cells for 3 d, replacing the medium every 24 h (three times). ADE is specified over a three-day period with medium changes every 24 h until the third day (day 8), when hepatic differentiation may be induced as described in Step 7. The typical morphology of cells undergoing differentiation can be seen in Figure 2 .  crItIcal step Anteriorizing the endoderm takes 3 d and is counted from day 5, including day 5, day 6 and all of day 7. On day 8, cells are then specified to the hepatic lineage as described in Step 11. Figure 4a .  crItIcal step The medium should be changed every second day during the maturation phase of the differentiation protocol. Morphological characteristics of hepatocytes such as polygonal shape, multinucleated cells, canaliculi-like structures appear at approximately day 15 of the protocol along with expression of genes such as AFP and CYP3A7. ALB, APOF and SERPINA1 can be detected in the medium as early as on day 15, and inducible cytochrome P450 activity can be observed • tIMInG Steps 1-5 (day 0): ~2 h will be required to passage and plate cells for maintenance and experimental purposes
Step 6 (day 1): only a medium change is required and should take 10-20 min
Step 7 (day 2): the first day of differentiation requires ~30 min to prepare the medium, aspirate the previous medium and replace it with fresh medium DE differentiation is the most important part of the protocol. Indeed, artificial hepatocytes are systematically obtained as long this step of the protocol works efficiently. Thus, optimization of the first part of the protocol is essential. We recommend defining the most efficient concentration of FGF and CHIR in Step 1.
To do so, cells should be differentiated in increasing/decreasing doses of CHIR and/or bFGF; DE differentiation can then be monitored using qPCR, immunocytochemistry and flow cytometry analyses. At least 60% of the cells should express endodermal markers to ensure an efficient hepatic differentiation 11 Suboptimal differentiation BMP-4 effect BMP-4 might have a negative effect on hepatoblast specification in some hPSC lines. Thus, Step 7 can be replaced by extending Step 6 for three additional days (i.e., three additional days in RPMI/B-27 supplemented with activin). Notably, increasing or decreasing the dose of BMP-4 has no effect on hepatoblast specification in vitro
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Suboptimal maturation Variability between lines
Hepatoblast-derived hPSCs respond differentially to a variety of basal cell culture media and thus optimization might be necessary for specific cell lines. Hepatozyme can be used instead of HBM
